01—Abstract
Summary
Summary of the 8-K filed October 30, 2024. Cited figures are marked; the original filing is the authoritative source.
Biogen reported third quarter 2024 results on October 30, 2024, with total revenue of $2.47 billiona, down 3% year over year, and GAAP diluted EPS of $2.66 versus a GAAP loss of $(0.47) a year earlier.
Non-GAAP diluted EPS was $4.08b, down 6% from $4.36. The top-line decline was driven by a 9% drop in multiple sclerosis (MS) product revenue, which was partly offset by 10% growth in rare disease revenue (SPINRAZA, SKYCLARYS, QALSODY), a 6% rise in anti-CD20 program revenue, and new launches including ZURZUVAE (about $22 million) and LEQEMBI (about $67 million global in-market sales). Contract manufacturing, royalty and other revenue fell 18%.
Margins improved: non-GAAP cost of sales fell to 24% of revenue from 26%, and GAAP and non-GAAP R&D and SG&A declined sharply year over year, largely because of one-time 2023 Reata equity compensation charges and ongoing Fit for Growth cost reductions. Management raised full-year 2024 non-GAAP diluted EPS guidance to $16.10 to $16.60c from $15.75 to $16.25, implying about 11% growth at the midpoint versus 2023. Total revenue is still expected to decline by a low-single-digit percentage, and operating income is now expected to grow at a high-teens percentage.
Pipeline news was a major focus: the dapirolizumab pegol Phase 3 trial in lupus met its primary endpoint, felzartamab received FDA Breakthrough Therapy Designation for antibody-mediated rejection, and nusinersen's higher-dose regimen showed statistically significant improvement in DEVOTE. Biogen and Sage also decided to stop developing zuranolone for major depressive disorder. From a balance sheet perspective, Q3 free cash flow was about $901 milliond, and net debt was about $4.6 billion ($6.3 billion total debt against $1.7 billion cash and securities).
No shares were repurchased in the quarter, leaving about $2.1 billion under the authorization. Investors should watch how fast new launches can offset the MS erosion, the timing of the lupus and nusinersen filings, and whether the EPS raise holds given the ongoing revenue decline.
02—Key points
Key Highlights
- Q3 2024 total revenue of $2,466 million, down 3% year over year; MS product revenue fell 9% to $1,054 million, while rare disease revenue rose 10% to $495 million.
- GAAP diluted EPS of $2.66 versus a GAAP loss of $(0.47) in Q3 2023, which was inflated by one-time Reata acquisition equity compensation charges in the prior year; non-GAAP diluted EPS was $4.08, down 6%.
- Full-year 2024 non-GAAP diluted EPS guidance raised to $16.10–$16.60 (from $15.75–$16.25), implying about 11% growth at the midpoint versus 2023; total revenue still expected to decline by a low-single-digit percentage.
- Operating income now expected to grow at a high-teens percentage in 2024, with a mid-single-digit percentage point operating margin improvement maintained.
- Non-GAAP cost of sales improved to 24% of total revenue from 26%, driven by product mix and lower idle capacity charges; non-GAAP R&D fell 9% and non-GAAP SG&A was roughly flat.
- Pipeline milestones: dapirolizumab pegol Phase 3 met its primary endpoint in SLE; felzartamab received FDA Breakthrough Therapy Designation; nusinersen higher-dose DEVOTE cohort showed statistically significant improvement; zuranolone for MDD discontinued.
- Free cash flow of about $901 million in Q3 2024, with net debt of about $4.6 billion and no share repurchases during the quarter (about $2.1 billion remaining under the authorization).
03—Questions
Frequently Asked Questions
Why did Biogen's GAAP EPS swing from a loss to a $2.66 profit year over year?
The Q3 2023 GAAP loss was driven by roughly $197 million of equity-based compensation tied to the Reata acquisition, along with large losses on equity investments and restructuring charges. In Q3 2024, GAAP results benefited from lower R&D and SG&A, a $39 million gain on equity investments, and the absence of those one-time Reata charges, though the quarter still included about $46 million of inventory step-up amortization and HI-Bio-related compensation.
Is the raised guidance a sign that the underlying business is growing?
Not on the top line. Management still expects total revenue to decline by a low-single-digit percentage in 2024, and core pharmaceutical revenue is expected to be roughly flat. The EPS raise reflects margin improvement and cost reductions from the Fit for Growth and R&D prioritization programs, plus operating income growth, rather than revenue growth.
Can new launches offset the decline in multiple sclerosis revenue?
So far only partly. MS revenue fell 9% in Q3, and new launches such as rare disease products, ZURZUVAE, and LEQEMBI are growing sequentially. Rare disease revenue rose 10%, but total product revenue still declined 2%. Management says launches are increasingly offsetting MS erosion, but the full-year revenue guidance implies the offset is not yet complete.
What do the pipeline updates mean for investors?
The dapirolizumab pegol Phase 3 lupus win, the felzartamab Breakthrough designation, and the positive nusinersen high-dose data all support future regulatory filings and potential new revenue streams. However, these programs are still in late-stage development, and the discontinuation of zuranolone is a setback. Results from later-stage trials and regulatory decisions remain uncertain.
How strong is Biogen's balance sheet and capital return position?
Biogen generated about $901 million of free cash flow in Q3 and held about $1.7 billion in cash and marketable securities against about $6.3 billion of total debt, leaving net debt of about $4.6 billion. Total debt has come down from the prior year, and the company has about $2.1 billion remaining under its buyback authorization. However, it repurchased no shares in the quarter, so near-term capital returns are limited.
04—Continue